William Diebold, MD
Psychiatry · Johnson City, TNNPI 1770573511
Payments from drug & device makers
Across 178 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$599
- Otsuka America Pharmaceutical, Inc.$542
- Vanda Pharmaceuticals Inc.$402
- Neurocrine Biosciences, Inc.$343
- AbbVie$222
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$208
- plus $818 from 10 others
What the payments were for
- Food & beverage$3,135100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 35 | $599 |
| Otsuka America Pharmaceutical, Inc. | 31 | $542 |
| Vanda Pharmaceuticals Inc. | 23 | $402 |
| Neurocrine Biosciences, Inc. | 19 | $343 |
| AbbVie(2 entities) | 13 | $222 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $208 |
| Lundbeck LLC | 12 | $196 |
| Sunovion Pharmaceuticals Inc. | 11 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $132 |
| Axsome Therapeutics, Inc. | 6 | $117 |
| Johnson & Johnson | 4 | $66 |
| Alkermes, Inc. | 3 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Indivior Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
How this compares
$3,135 in reported general payments places this provider in the 80th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Effexor XrVenlafaxine Hcl | 24 | $19,825 |
| Quetiapine Fumarate | 362 | $6,364 |
| Clonazepam | 290 | $3,321 |
| Aripiprazole | 128 | $3,286 |
| Gabapentin | 226 | $3,257 |
| Alprazolam | 573 | $2,889 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 66 | $2,869 |
| Methylphenidate Hcl | 78 | $2,723 |
| Risperidone | 130 | $1,927 |
| Bupropion Hcl SrBupropion Hcl | 92 | $1,898 |
| Mirtazapine | 99 | $1,451 |
| Sertraline Hcl | 162 | $1,280 |
| Lorazepam | 196 | $1,197 |
| Diazepam | 139 | $1,070 |
| Fluoxetine Hcl | 154 | $1,048 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Johnson City
- Brian BonfardinJohnson City$2.6M
- John FenleyJohnson City$1.4M
- George BrownJohnson City$91K
- Kevin TurnerJohnson City$9K
- Rakesh AminNashville$3M
- Paul NewhouseNashville$1.4M
- Anita VarmaMemphis$1.3M
- Patricia AndrewsNashville$748K
- David SnowMaryville$605K
- Jonathan BeckerBrentwood$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.